Re-analysis of large trials shows greatest benefit of chemotherapy in ER-negative tumors
Despite the common belief in the oncology community that cancer research and treatment have focused on breast tumors that are estrogen receptor (ER)-positive, a researcher from The University of Texas M. D. Anderson Cancer Center maintains that clinicians have made "enormous strides" in treating patients with tumors that are ER-negative.
In a presentation at the annual meeting of the San Antonio Breast Cancer Symposium, Donald Berry, Ph.D., a professor and chair of the Department of Biostatistics and Applied Mathematics, looked at decades of breast cancer clinical trial experience and found that "the benefit of chemotherapy advances over the last 20 years to ER-negative patients has been surprisingly dramatic."
In examining the impact of chemotherapy treatment of node-positive breast cancer in three national clinical trials, which enrolled more than 6,000 patients cumulatively, Berry found that chemotherapy has reduced the risk of death in ER-negative patients by 56 percent. "The absolute benefit has been similarly impressive, especially in comparison with the corresponding absolute benefit of chemotherapy to ER-positive patients," he says.
The studies, conducted by the Cancer and Leukemia Group B (CALGB) and the U.S. Breast Intergroup, all tested different chemotherapy regimens and doses in women whose cancer had spread to their lymph nodes, and all three showed statistically significant results. But, patients were treated "irrespective of hormone sensitivities or whether they had received tamoxifen or not," Berry says. In women who are ER-positive, tamoxifen and other SERMs (selective estrogen receptor modulators) have been shown to help prevent cancer development or recurrence.
The impact of such preventive treatments, however, was not "weighted" in these trials, he says. "People accept and act as though chemotherapy is equally beneficial independent of ER status," he says. In his analysis, Berry found that all three studies show that chemotherapy provided a statistically significant benefit for patients with ER-negative tumors, but "only a little bit of an effect for ER-positive tumors that had been treated with tamoxifen, and none of the trials showed a statistically significant benefit for higher doses of chemotherapy in ER-positive patients."
Berry says that the results will likely surprise oncologists "because everyone has assumed that ER status doesnt matter in chemotherapy treatment, but here we show it does." That doesnt mean, however, that patients with ER-positive tumors should not receive chemotherapy, Berry warns.
He adds that the study proves that breast cancer patients of both hormonal types are being aided by clinical advances. "The prevailing wisdom has been that science has focused on ER-positive tumors, with development of SERMs and now aromatase inhibitors, but ER-negative patients have been left in the lurch," Berry says. "Not so. This analysis demonstrates that chemotherapy use has more than doubled survival rates in women with ER-negative tumors."
Nancy Jensen | EurekAlert!
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.
Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...